Vandetanib; Uses,Dosage, Side Effects, Interactions, Pregnancy Vandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2, thereby blocking stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor, a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. or Vandetanib is a multi-kinase inhibitor that is used in the therapy of advanced or metastatic medullary thyroid cancer. Vandetanib therapy is commonly associated with transient elevations in serum aminotransferase during therapy, but has not been linked to cases of clinically apparent acute liver injury with jaundice. Mechanism of Action of Vandetanib Vandetanib is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases.VEGFR- and EGFR-dependent signaling are both clinically validated pathways in cancer, including non-small-cell lung cancer (NSCLC). RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer has led to orphan-drug designation by the regulatory authorities in the USA and EU. or Oncogenic conversion of the RET /rearranged during transfection/ tyrosine kinase is a frequent feature of medullary thyroid carcinoma (MTC). Vandetanib is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. In this study, vandetanib mechanism of action in TT and MZ-CRC-1 human MTC cell lines, carrying cysteine 634 to tryptophan (C634W) and methionine 918 to threonine (M918T) RET mutation respectively /were studied/. Vandetanib blunted MTC cell proliferation and RET, Shc and p44/p42 mitogen-activated protein kinase (MAPK) phosphorylation. Single receptor knockdown by RNA interference showed that MTC cells depended on RET for proliferation. Adoptive expression of the vandetanib-resistant V804M RET mutant rescued the proliferation of TT cells under vandetanib treatment, showing that RET is a key vandetanib target in these MTC cells. Upon RET inhibition, adoptive stimulation of EGFR partially rescued TT cell proliferation, MAPK signaling, and expression of cell-cycle-related genes. This suggests that simultaneous inhibition of RET and EGFR by vandetanib may overcome the risk of MTC cells to escape from RET blockade through compensatory over-activation of EGFR. Source – PubMed Indications of Vandetanib Thyroid Cancer Acne Acne Vulgaris Actinomycosis Anthrax Intestinal Amebiasis Listeria infection Meningococcal Infections Meningococcal Meningitis Metastatic Medullary Thyroid Cancer Locally advanced Medullary thyroid cancer Vandetanib is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before an individual treatment decision Contra-Indications of Vandetanib Hypothyroidism Low amount of magnesium in the blood Low amount of calcium in the blood low amount of potassium in the blood High blood pressure Very rapid heartbeat Prolonged QT interval on EKG Heart failure Abnormal EKG with QT changes from Birth Lack of Blood Supply to the brain Severe Diarrhea Pregnancy A Mother who is Producing Milk and Breastfeeding Moderate to Severe Kidney Impairment Lung Tissue Problems Brain-Capillary Leak Syndrome Dosage of Vandetanib Strengths: 100 mg; 300 mg Thyroid Cancer Initial dose: 300 mg orally once daily.Duration of therapy: Continue drug until disease progression or unacceptable toxicity occurs. Side Effects of Vandetanib The most common chest pain certainly hair loss a headache joint painPain dizziness nausea and vomiting Severe stomach ache epigastric pain, diarrhea, anorexia, flatulence, a headache, dizziness, fainting, fast or pounding heartbeats. More common Fast or irregular heartbeat appetite loss changes in nails constipation fatigue fever Back pain dizziness a headache increased cough Acid or sour stomach decreased appetite Agitation chest congestion chest pain cold sweats confusion decreased sexual ability or desire stomach or abdominal cramps, gas, or pain trouble sleeping Less common bleeding gums blood in the urine or stools chest pain diarrhea Burning, crawling, itching, numbness, prickling, “pins and needles“, or tingling feelings difficulty in moving muscle stiffness redness of the face, neck, arms and occasionally, upper chest lack or loss of strength muscle spasm difficult or labored breathing dry mouth headache irritability lack or loss of strength loose stools loss of interest or pleasure muscle stiffness night sweats passing gas stomach discomfort, upset, or pain swollen joints trouble concentrating increased blood pressure Drug Interactions of Vandetanib Vandetanib may interact with following drugs ,suppliments & may decrease the efficacy of drug alpha blockers (e.g., alfuzosin, doxazosin, silodosin, tamsulosin) anticancer medications (e.g., cabazitaxel, docetaxel, doxorubicin, etoposide, ifosfamide, irinotecan, vincristine) “azole” antifungal medications (e.g., fluconazole, itraconazole, ketoconazole) beta-blockers (e.g., atenolol, propranolol, metoprolol) barbiturates (e.g., butalbital, pentobarbital, phenobarbital) benzodiazepines (e.g., chlordiazepoxide, clonazepam, diazepam, lorazepam) calcium channel blockers (e.g., nifedipine, diltiazem, verapamil, amlodipine, felodipine) carbamazepine chloroquine corticosteroids (e.g., dexamethasone, prednisone, methylprednisolone) cyclosporine dantrolene “gliptin” diabetes medications (e.g., linagliptin, saxagliptin, sitagliptin) losartan macrolide antibiotics (e.g., azithromycin, clarithromycin, erythromycin) metronidazole mirtazapine montelukast norfloxacin ondansetron carbamazepine phenytoin progestins (e.g., dienogest, levonorgestrel, medroxyprogesterone, norethindrone) proton pump inhibitors (PPIs; e.g., esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, duloxetine, fluoxetine,paroxetine, sertraline) sildenafil “statin” anticholesterol medications (e.g., atorvastatin, lovastatin, simvastatin) tacrolimus tadalafil tetracycline theophylline tocilizumab tolterodine tramadol other selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, fluoxetine, sertraline) 5-HT3 antagonists (e.g., granisetron, ondansetron) tamsulosin tapentadol thiazide diuretics (e.g., hydrochlorothiazide, indapamide) tramadol tricyclic antidepressants (e.g., nortriptyline, amitriptyline, imipramine, trimethoprim other tyrosine kinase inhibitors (e.g., dasatinib, imatinib, nilotinib, sunitinib) tetracycline tocilizumab vandetanib vemurafenib vitamin C Pregnancy & Lactation of Vandetanib FDA Pregnancy Category D Pregnancy This medication may cause harm to an unborn fetus and should not be used during pregnancy. If you become pregnant while taking this medication, contact your doctor immediately. Women of childbearing age who are taking vandetanib should use an effective method of birth control (e.g., birth control pill, condoms) during treatment and for at least 3 months after the last dose of vandetanib.Men receiving this medication must use an effective method of contraception during treatment and for two months following the last dose. Lactation It is not known if vandetanib passes into breast milk. If you are a breastfeeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breastfeeding. References DrugBank http://www.drugbank.ca/drugs/DB05294 http://www.drugbank.ca/drugs/DB05294#targets http://www.drugbank.ca/drugs/DB05294#transporters http://www.drugbank.ca/drugs/DB05294#carriers http://www.drugbank.ca/drugs/DB05294#enzymes https://www.drugs.com/cdi/vandetanib.html https://www.drugs.com/cdi/vandetanib.html EPA DSStox https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID1046681 ClinicalTrials.gov https://clinicaltrials.gov/ DailyMed https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=VANDETANIB FDA Pharm Classes https://www.accessdata.fda.gov/spl/data/a4a5b17f-dd2b-4417-91cf-98697b8f7230/a4a5b17f-dd2b-4417-91cf-98697b8f7230.xml https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm https://www.webmd.com/drugs/2/drug-155643/vandetanib-oral/details/list-contraindications LiverTox https://livertox.nlm.nih.gov/Vandetanib.htm NCIT https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C2737 FDA/SPL Indexing Data https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/ EU Community Register of Medicinal Products https://ec.europa.eu/health/documents/community-register/html/h749.htm HSDB https://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+443913-73-3 WHO ATC https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ European Chemicals Agency (ECHA) https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/200538 European Chemicals Agency – ECHA https://www.echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database/-/discli/details/200538 FDA Medication Guides https://www.fda.gov/downloads/Drugs/DrugSafety/UCM250399.pdf FDA Orange Book https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm MassBank of North America (MoNA) http://mona.fiehnlab.ucdavis.edu/spectra/browse?inchikey=UHTHHESEBZOYNR-UHFFFAOYSA-N NCI Cancer Drugs https://www.cancer.gov/about-cancer/treatment/drugs/vandetanib PubMed Health http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0012607/ Springer Nature Read more … Wikipedia https://en.wikipedia.org/wiki/Vandetanib https://pubchem.ncbi.nlm.nih.gov Show More